QNTM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

QN

Mkt Cap

$20.2M

Volume

180.45K

Next Earnings

November 6th

Loading chart

QN

QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares

QNTM

Pay with—

Available Balance0.00

QN

Mkt Cap

$21.9M

Volume

180.45K

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple SclerosisQuantum BioPharma has entered into a Study Start-Up Agreement with Thermo Fisher Scientific's PPD Clinical Research Business to implement its Phase 2 clinical trial of Lucid-MS, an investigational neuroprotective therapy targeting demyelination in progressive multiple sclerosis. The agreement marks a significant milestone following FDA clearance and represents the initiation of formal study start-up activities.GlobeNewswire Inc. · Oct 6, 2026

Quantum BioPharma Announces Closing of Debt SettlementQuantum BioPharma Ltd. closed a debt settlement of CAD$123,487.43 by issuing 30,948 Class B subordinate voting shares to creditors at CAD$3.99 per share. The company is a biopharmaceutical firm developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, with its lead compound Lucid-MS in preclinical development.GlobeNewswire Inc. · Jul 30, 2026

Quantum BioPharma Announces Intention to Settle DebtQuantum BioPharma Ltd. announced that its board of directors approved a debt settlement of CAD$123,487.43 to creditors and insiders through the issuance of Class B subordinate voting shares at a deemed price based on the lower of CAD$4.26 or the CSE closing price on the trading day prior to settlement closing.GlobeNewswire Inc. · Jul 20, 2026

Quantum BioPharma Provides Corporate UpdateQuantum BioPharma announced that its Lucid-MS (Lucid-21-302) investigational drug for multiple sclerosis treatment has been placed on clinical hold by the FDA pending submission of additional information. The company believes the issues are addressable and plans to submit a response package. Previously disclosed timelines for FDA review, Phase 2 trial initiation, and data milestones have been withdrawn. Additionally, Dr. Lakshmi P. Kotra resigned as director but will remain as a senior clinical advisor.GlobeNewswire Inc. · Jun 1, 2026

Quantum BioPharma Provides Corporate UpdateQuantum BioPharma has engaged two marketing firms—Senergy Communications Capital Inc. and King Tide Media LLC—to provide marketing and investor awareness services starting May 2026. The company will pay USD $150,000 to Senergy and USD $125,000 to KTM for corporate branding, social media, and advertising initiatives on one-month contracts with renewal options.GlobeNewswire Inc. · Apr 27, 2026

Quantum Biopharma Provides Corporate UpdateQuantum BioPharma Ltd. granted 35,000 stock options to employees and consultants, exercisable at CA$6.50 for five years. The options vest immediately and are subject to a four-month hold period. The grant was made under the company's shareholder-approved stock option plan.GlobeNewswire Inc. · Mar 27, 2026

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement OfferingQuantum BioPharma Ltd. has closed the first tranche of its debenture unit offering, raising $3.75 million CAD from 3,750 Debenture Units. The company also completed an initial batch of debt settlement by issuing 370,457 Class B subordinate voting shares to settle approximately $1.12 million CAD of debt owed to creditors and insiders. Proceeds will be used for business development and working capital.GlobeNewswire Inc. · Mar 20, 2026

Quantum BioPharma Provides Corporate UpdateQuantum BioPharma Ltd. announced revised terms for its Debenture Units offering following a decrease in its Class B subordinate voting share price. The company reduced the conversion price per share to $3.00, increased warrant allocation to 333.33 per unit, and lowered the exercise price per warrant share to $3.75. The debt settlement will also be completed at the reduced conversion price.GlobeNewswire Inc. · Mar 11, 2026

Quantum BioPharma Provides Corporate UpdateQuantum BioPharma announced a non-brokered private placement offering of up to 4,000 convertible debenture units at $1,000 each, with 1.25% monthly interest and a 24-month maturity. The company also plans to settle creditor and insider debts through share issuance at $4.00 per share. Proceeds will support business development and working capital.GlobeNewswire Inc. · Mar 10, 2026

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC) alleging they engaged in market manipulation by placing spoofed sell orders to artificially deflate Quantum Biopharma Ltd. stock prices, then purchasing shares at depressed levels for profit. Investors who sold Quantum securities between January 6, 2021 and October 15, 2025 are encouraged to join the case.GlobeNewswire Inc. · Feb 19, 2026

to start trading

QN

QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares

QNTM

Pay with—

Available Balance0.00

Your PositionYou don't own any QNTM yet.

Related Tickers

Earnings